Pharma & Biotech Global Week in Review 9 Dec 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

(Daflon) Diosmin – Spain: Central Administrative Court of Appeal rules holders of innovator medicaments not entitled to challenge marketing approvals of generics by AEMPS (Patent Baristas)

Surfaxin (Lucinactant) – US: PTO rules on the availability of multiple interim patent extensions (FDA Law Blog)

Viread (Tenofovir) – India: Gilead files appeal in IPAB challenging IPO’s rejection of Viread patents (GenericsWeb)

 
General

Oxfam: ACTA could hurt poor countries (Michael Geist)

HIV medicines and patent-pooling: Making it happen? (IPKat)

HIV/AIDS treatment access policies: Emerging incentives for pro-poor changes to IP? (IP Watch)

Future of Biotechnology and IP: Research exemptions, ceilings, trade secrets (IP Watch

WTO riots ten years later: the tension continues between trade and rights – seizure of Indian made pharmaceuticals in transit to Brazil (Seattle Trademark Lawyer)

Canada: Access to Medicines Bill clears second reading (Michael Geist)

India: Open Source Drug Discovery still well on track (Spicy IP)

India: Challenging pre-grant orders through writs: Whither ‘alternative remedies’?: Roche v Cipla (Spicy IP)

India, intellectual property and biotechnology industry – to protect, or not to protect (Biotech Blog)

Italy: SPCs, competition and refusal to supply – Italian Competition Authority’s responses to ‘refusal to deal’ questionnaire (The SPC Blog)

US: Ariad v Lilly – amicus briefs by Regents of University of California et al and various companies (Patent Docs) (Patent Docs)

US: Ariad v Lilly – A look back at the roots of the thorny written description requirement (Patents4Life)

US: Disclosing ‘related cases’ at the Federal Circuit: Eli Lilly’s written description ‘secret’: Ariad v Eli Lilly; Lilly v Teva (Patently-O)

US: Breach of contract claims dismissed in dispute between Alzheimer’s Institute of America and the Mayo Clinic and Myriad pharmaceuticals over patents covering nucleic acids and methods for diagnosing and modelling Alzheimer’s disease (Patent Docs)

US: Two physicians want Congress to close ‘evergreening’ loophole in follow-on biologics legislation (Patent Docs)

 
Products

(Daflon) Diosmin – Spain: Central Administrative Court of Appeal rules holders of innovator medicaments not entitled to challenge marketing approvals of generics by AEMPS (Patent Baristas)

Adderall (Amphetamine, Dextroamphetamine) – Shire and Teva settle litigation concerning supply of Adderall XR authorised generic (SmartBrief) (GenericsWeb)

Cancidas (Caspofungin) – US: Complaint filed in New Jersey – Infringement of US patent following a Paragraph IV challenge: Merck & Co., Inc. et al. v. Teva Parenteral Medicines, Inc. et al. (Patent Docs)

Cialis (Tadalafil), Levitra (Vardenafil), Viagra (Sildenafil) – Israel Court releases impounded moped of impotence drug dealer: Israel Police Fraud Squad vs Gillert (IP Factor)

Effexor XR (Venlafaxine) – Mylan announces settlement agreement related to antidepressant (SmartBrief) (GenericsWeb)

Fuzeon (Enfuvirtide) – US: CAFC orders another case transferred out of Texas: In re Hoffmann-La Roche (Patently-O)

Glumetza (Metformin) – US: Complaint filed in N D California – Infringement of US patent following a Paragraph IV challenge: Depomed, Inc. v. Lupin Pharmaceuticals, Inc. et al. (Patent Docs)

Immutol and ImmuPet (Norwegian Beta-1,3/1,6-Glucan) – US: When (claimed) size matters – Biopolymer appeals summary judgment finding no infringement: Biopolymer v. Immunocorp (PATracer)

Lipitor (Atorvastatin) – US: Complaint filed in Delaware – Infringement of US patent following Paragraph IV challenge: Pfizer Inc. et al. v. Kremers Urban LLC et al. (Patent Docs)

Loprox, Vanos (Ciclopirox) – US: Settlement announced in Loprox and Vanos patent dispute between Glenmark and Medicis (Patent Docs)

Neupogen (Filgrastim) – US: E D Pennsylvania: Plaintiff seeks declaratory judgment of non-infringement and invalidity: Teva Pharmaceuticals USA, Inc. v. Amgen Inc. (Patent Docs)

Norvasc (Amlodipine) – Canada: Court of Appeal denies BIOTEC Canada’s and Eli Lilly’s leave to intervene in Pfizer’s appeal of Court’s decision to invalidate Amlodipine patent; Pfizer’s motion to amend appeal book, notice of appeal and memorandum of fact and law denied; ratiopharm’s motion to amend previous judgment on the merits denied: Pfizer v ratiopharm (Pharmacapsules @ Gowlings)

Nuvigil (Armodafinil) – US: Complaint filed in Delaware – Infringement of US patent following a Paragraph IV challenge: Cephalon Inc. et al. v. Teva Pharmaceuticals USA Inc. et al. (Patent Docs) (SmartBrief) (GenericsWeb)

OxyContin (Oxycodone) – US: Ranbaxy admits infringement in OxyContin suit – District Court S D New York approves consent judgment between Ranbaxy and Purdue Pharma (Patent Docs)

Reyataz (Atazanavir) – US: Complaint filed in Delaware: Infringement of US patent following a Paragraph IV challenge: Bristol-Myers Squibb Co. et al. v. Teva Pharmaceuticals USA Inc. (Patent Docs)

Rozerem (Ramelteon) – US: Complaint filed in Delaware: Infringement of US patent following a Paragraph IV challenge: Takeda Pharmaceutical Co. Ltd. et al. v. Watson Laboratories Inc. – Florida et al  (Patent Docs)

Surfaxin (Lucinactant) – US: PTO rules on the availability of multiple interim patent extensions (FDA Law Blog)

Taxotere (Docetaxel) – Canada: Federal Court refuses to grant Order of Prohibition against Hospira regarding Docetaxel product: Sanofi v Hospira (Pharmacapsules @ Gowlings)

Vigamox (Moxifloxacin) – US: Teva appeals verdict finding ANDA to market generic Vigamox infringes patent: Alcon Inc. v. Teva Pharmaceuticals (PATracer)

Viread (Tenofovir) – India: Gilead files appeal in IPAB challenging IPO’s rejection of Viread patents (GenericsWeb)

Yaz (Drospirenone, Ethinyl estradiol) – Canada: Court dismisses judicial review of Minister’s decision refusing to list formulation patent on the Patent Register: Bayer v Canada (Health) (Pharmacapsules @ Gowlings)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: